



FOR IMMEDIATE RELEASE:

Micron Urology Not Impacted by Nevro and Stimwave Settlement Agreement on High Frequency Usage

Micron Continuing Investigational Study for the World's First Office Based OAB Neuromodulator with Freedom to Operate Under Exclusive Licenses

BOCA RATON, Fla. (March 2, 2020) – Micron Medical Corporation, a privately-held, pre-commercial urology medical device company, today reiterates that the recent settlement agreement between Nevro and Stimwave has no impact on Micron's business and future commercialization plans. Micron maintains valid freedom-to-operate positions to utilize a suite of patents from both Micron Devices LLC, and Beaumont Health Systems. Micron Devices is an intellectual property holding and technology incubator that has over 46 issued patents in the field of wireless neurostimulator products. Micron Devices licenses spinal cord stimulation (SCS) related IP to Stimwave, which is the only party enjoined by the Nevro permanent injunction announced February 28, 2020.

Micron Medical Corporation's full product family includes neuromodulation therapies for incontinence, erectile and sexual dysfunction, and other urologic disorders. "Micron's exclusive licenses from both Micron Devices and Beaumont are not impacted whatsoever by the Stimwave-Nevro matter and settlement. Further, the SCS epidural approaches utilized by Stimwave-Nevro do not apply to any of the other Micron Devices' proprietary and patented technologies for any of the indications we explore beyond SCS, which include peripheral nerve pain, urology, joint pain, depression, migraines, sleep apnea, peripheral neuropathy, and many other advanced use cases for our novel wireless, injectable electroceutical products," said Laura Tyler Perryman, President of Micron Medical Corporation and managing director of Micron Devices LLC.

"We continue to be exclusively positioned to leverage our innovative platform technology to benefit an entirely new market with our wireless device urology solution, and are thrilled to bring this product to the US market, expected in the second half of this year." continued Mrs. Perryman.

The Micron device utilizes wireless technology to activate the afferent micturition (neural urinary) pathways and is placed through a needle at the tibial nerve in a minimally invasive, office-based procedure. The Micron device is pre-market, and investigational through the Food and Drug Administration Investigational Device Exemption for future premarket application. This device is in stark contrast to sacral nerve stimulation, which has been the gold-standard for incontinence neuromodulation for more than 20 years. Sacral nerve stimulation requires the patient receive the procedure in an operating room under anesthesia with fluoroscopic imaging, and involves implantation of electrodes at the sacral nerve with a battery unit that lasts up to four to five years, or alternatively would need to be recharged regularly often for newer models.

More than 37 million Americans – one out of every six adults – live with some level of OAB. OAB treatment varies depending on the severity of the symptoms, with the estimated cost to the U.S. healthcare system totaling more than \$60 billion per year.

About Micron Medical Corporation

Micron Medical Corporation is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. Micron's goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management. <https://micronmed.com/index.php>.

###